Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2B | P41595 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136027 | 0.89 | ASIC3 (0.39) | ASIC3HRH3KCNH2MCHR1HTR2C | |
| SCHEMBL4145172 | 0.87 | CD274 (0.39) | ASIC3HRH3KCNH2DRD2HTR2C | |
| SCHEMBL4135556 | 0.87 | CD274 (0.38) | ASIC3HTR7HRH3KCNH2GRIA1 | |
| SCHEMBL4135521 | 0.86 | CYP11B2 (0.35) | HRH3KCNH2DRD2HTR2CHTR2B | |
| SCHEMBL4141100 | 0.86 | HRH3 (0.38) | ASIC3HRH3KCNH2DRD2 | |
| SCHEMBL4130044 | 0.85 | HRH3 (0.37) | ASIC3HRH3KCNH2MCHR1HTR2C | |
| SCHEMBL4132423 | 0.85 | SIGMAR1 (0.38) | ASIC3HTR7HRH3HTR2CHTR2B | |
| SCHEMBL4129121 | 0.84 | HRH3 (0.39) | ASIC3HRH3KCNH2 | |
| SCHEMBL4140206 | 0.84 | HRH3 (0.40) | ASIC3HRH3KCNH2MCHR1HTR2C | |
| SCHEMBL4142343 | 0.84 | HRH3 (0.40) | ASIC3HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | ASIC3 388/4885HTR7 7/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.